ReviewDrug design, development and therapy2015
Profile of atacicept and its potential in the treatment of systemic lupus erythematosus.
Review in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders.Frontiers in immunology · 2020Pooled it
- A Comprehensive Review of Biological Agents for Lupus: Beyond Single Target.Frontiers in immunology · 2020Pooled it
- Exploring the depths of IgG4: insights into autoimmunity and novel treatments.Frontiers in immunology · 2024Review
- Population pharmacokinetics of atacicept in systemic lupus erythematosus: An analysis of three clinical trials.CPT: pharmacometrics & systems pharmacology · 2023Article
- Promising Experimental Treatments for Lupus Nephritis: Key Talking Points and Potential Opportunities.Research and reports in urology · 2023Review
- Advancing Biologic Therapy for Refractory Autoimmune Hepatitis.Digestive diseases and sciences · 2022Review
- Treat-to-target in systemic lupus erythematosus: advancing towards its implementation.Nature reviews. Rheumatology · 2022Review
- Kinetics of free and ligand-bound atacicept in human serum.Frontiers in immunology · 2022Article
- Identifying Safety Thresholds for Immunosuppressive Drugs: Applying Insights from Primary Antibody Deficiencies to Mitigate Adverse Events in Secondary Antibody Deficiencies Using Mathematical Modeling of Preclinical and Early Clinical Data.European journal of drug metabolism and pharmacokinetics · 2021Review
- Article
- Integrated safety profile of atacicept: an analysis of pooled data from the atacicept clinical trial programme.Rheumatology advances in practice · 2019Article
- Efficacy and safety of tacrolimus in induction therapy of patients with lupus nephritis.Drug design, development and therapy · 2019Article
- The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management.Frontiers in immunology · 2019Review
- TACI-Deficient Macrophages Protect Mice Against Metaflammation and Obesity-Induced Dysregulation of Glucose Homeostasis.Diabetes · 2018Article
- Toward Small-Molecule Inhibition of Protein-Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions.Current topics in medicinal chemistry · 2018Review
- Crosstalk Between T and B Cells in the Germinal Center After Transplantation.Transplantation · 2017Review
- Pathways of impending disease flare in African-American systemic lupus erythematosus patients.Journal of autoimmunity · 2017Article
- Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus.Clinical pharmacokinetics · 2017Review
- Targeting B cells in treatment of autoimmunity.Current opinion in immunology · 2016Review
- Update on Biologic Therapies for Systemic Lupus Erythematosus.Current rheumatology reports · 2016Review
Corrections and comments
- Erratum issuedProfile of atacicept and its potential in the treatment of systemic lupus erythematosus [Corrigendum].2015 · Cogollo, Estafania [corrected to Cogollo, Estefania]
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The importance of B cell activating factors in the generation of autoantibodies in patients with systemic lupus erythematosus (SLE) is now recognized. The two key factors, known as BAFF and APRIL, produced by a variety of cells including monocytes, dendritic cells and T cells, also help to regulate B cell maturation, function and survival. Biologic agents that block these factors have now been developed and tried out in large scale clinical trials in SLE patients. Benlysta which blocks BAFF has met some of its end points in clinical trials and is approved for use in patients with skin and joint disease who have failed conventional drugs. In contrast, clinical trials using atacicept which blocks both BAFF and APRIL have been more challenging to interpret. An early study in lupus nephritis was, mistakenly, abandoned due to serious infections thought to be linked to the biologic when in fact the dramatic fall in the immunoglobulin levels took place when the patients were given mycophenolate, prior to the introduction of the atacicept. Likewise the higher dose arm (150 mgm) of a flare prevention study was terminated prematurely when 2 deaths occurred. However, the mortality rate in this study was identical to that seen in the Benlysta studies and a post hoc analysis found a highly significant benefit for the 150mgm arm compared to the lower dose (75 mgm) and placebo arms. Other trials with both Benlysta and atacicept are on-going.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.